Update on Nightingale Health Plc’s business targets for fiscal year 2021 – 2022

company release, July 5, 2022 at 08:30 (EST)

Inside information

Nightingale Health’s fiscal year ended June 30, 2022. During the 2021 – 2022 financial year, Nightingale Health achieved the following business objectives disclosed in the financial statement release issued on September 15, 2021:

  • Launch of a commercial service based on home testing
  • Launch of a new version of the company’s mobile application
  • Signature of an international commercial partnership agreement

In addition, the company reached several other milestones during the year, such as the launch of a new wellness service with Terveystalo, the largest healthcare provider in Finlandlaunch of a preventive health service in Japan and acquisitions of Yolife GmbH and Negen Oy.

Nightingale did not meet the following business targets in fiscal year 2021 – 2022:

  • FDA (US Food and Drug Administration) approval (approval process still ongoing)
  • Achieve an order book of 5 million euros (order book reached 3.8-4.0 million eurosi.e. approximately 1.5 times more than at the end of the previous financial year)

Launch of a commercial service based on home testing

Nightingale Health and the large Finnish pharmacy chain Yliopiston Apteekki have entered into a national distribution agreement for Nightingale Health’s home testing solution. A service based on the Nightingale Home service model has been made available to Yliopiston Apteekki’s online store at December 2021. The service also became available at Yliopiston Apteekki pharmacies in spring 2022.

Launch of a new version of the company’s mobile application

A new version of Nightingale Health’s the mobile application was launched in March 2022when the company launched a Livit consumer service by Nightingale Health. The service uses Nightingale Health’s home testing solution, allowing consumers to use the service without having to visit a lab. The new mobile app offers a wide variety of unique results to Nightingale Health. Results include the following metrics analyzed from a fingertip blood sample: Healthy Years, Heart Disease Resistance, Heart Age, Diabetes Resistance, Mind Resilience, Immune Resilience, and Immune Age, as well as several contributors to blood tests (Cholesterol Balance, Fatty Acid Balance, Dietary Fatty Acids, Low-Grade Inflammation, and Metabolic Efficiency).

Signature of an international commercial partnership agreement

In June 2022, Nightingale Health signed a partnership agreement with Physitrack Plc, a leader in global digital health. Business partnership expands Livit service availability to Germanythe UKand in the Nordic countries by adding Livit as a key feature for Physitrack’s Access wellness product. The Livit service is already available via Physitrack in Swedenand will be available in UK and Germany later in the year 2022.

FDA (US Food and Drug Administration) approval

Nightingale Health is in the process of seeking FDA approval that allows the use of Nightingale Health’s analysis technology in diagnostic healthcare solutions in United States. The processing time for the application has taken longer than expected, for reasons not attributable to the company, and the approval has not yet been granted. Nightingale Health will continue the process with the FDA and obtaining FDA approval remains a business objective for fiscal year 2022-2023.

Achieve an order book of 5 million euros

Nightingale Health’s the backlog at the end of the 2021 – 2022 financial year was 3.8-4.0 million euros (preliminary). The order book mainly contains international trade commitments to professional customers. The order backlog is approximately 1.5 times greater than the order backlog at the end of the 2020 – 2021 fiscal year.

Nightingale Health will publish its publication of the financial statements for July 1, 2021June 30, 2022 Thursday, September 29, 2022.

For more information, please contact:Teemu SunaCEO
[email protected]

Certified Advisor:
Oaklins Merasco Ltd. Phone. +358 9 6129 670

About Nightingale Health
Nightingale Health is The preventive health society. Staying healthy is one of the main priorities in human life. Our health has a profound impact on our quality of life, and it is also strongly linked to the lives of our loved ones. Nightingale Health enables prevention by combining the power of our in-house developed advanced blood testing technology with unparalleled access to global health repositories and cutting-edge medical research. With this combination, we go beyond traditional health care and wellness tools: we provide the scientific link to multiple health and disease outcomes and the ability to predict future healthy years.

https://news.cision.com/nightingale-health/r/update-on-nightingale-health-plc-s-business-targets-for-financial-year-2021—2022,c3596543

(c) Decision 2022. All rights reserved., sources Press Releases – English

Comments are closed.